Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

Autor: Rafael San-Juan, Mario Fernández-Ruiz, Francisco López-Medrano, Octavio Carretero, Antonio Lalueza, Guillermo Maestro de la Calle, María Asunción Pérez-Jacoiste Asín, Héctor Bueno, José Manuel Caro-Teller, Mercedes Catalán, Cristina de la Calle, Rocío García-García, Carlos Gómez, Rocío Laguna-Goya, Manuel Lizasoáin, Joaquín Martínez-López, Julia Origüen, Ángel Sevillano, Eduardo Gutiérrez, Borja de Miguel, Fernando Aguilar, Patricia Parra, Mar Ripoll, Tamara Ruiz-Merlo, Hernando Trujillo, José Luis Pablos, Estela Paz-Artal, Carlos Lumbreras, José María Aguado

Publikováno v: International Journal of Infectious Diseases
International Journal of Infectious Diseases, Vol 117, Iss, Pp 56-64 (2022)

Background: Controversy remains about the efficacy of tocilizumab (TCZ) for the treatment of severe COVID-19. We aimed to analyze the profile of TCZ-respondent patients. Methods: We retrospectively analyzed a cohort of patients with severe COVID-19 w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acc8c1e31738c5ea88d1147f0a289adf
https://doi.org/10.1016/j.ijid.2022.01.040